Inmunoterapia en 1L del CPCNP: monoterapia y/o tratamiento combinado - page 25

Nivo+CT=CheckMate 012
Rizvi NA, et al. JCO 2016
* Most commonly reported (>30%): fatigue, nausea, decreased appetite and alopecia
* Most common G3-4 AEs (>5%): pneumonitis (13%), fatigue, and acute renal failure
* Consider a preliminary 23% of Infusion-related reaction rate
1...,15,16,17,18,19,20,21,22,23,24 26,27,28,29,30,31,32,33,34,35,...42
Powered by FlippingBook